Abstract:Hepatocellular carcinoma (HCC) is one of the most common types of human malignancy worldwide, which is becoming increasingly resistant to traditional drug treatments. Puerarin combined with 5-fluorouracil (5-FU) may be a useful treatment for liver cancer. The primary aim of the present study was to determine whether combined treatment with 5-FU and puerarin is more effective against the hepatocellular carcinoma (HCC) cell line, SMMC7721, than treatment with 5-FU or puerarin alone. The growth inhibition of SMMC7721 cells by puerarin or 5-FU alone or in combination was determined by the Cell Counting Kit-8 assay, in vitro. Apoptotic morphological features and the percentage of apoptotic cells were detected using Hoechst 33258 staining and an Annexin V/PI apoptosis kit, respectively. In addition, a tumor xenograft model was established in nude mice using SMMC7721 cells. Puerarin and 5-FU alone or in combination were injected into the mice, and the inhibition of tumor growth was evaluated by monitoring tumor volume and weight. Treatment with 6,400 or 640 mu M 5-FU resulted in growth inhibition of 95.56 +/- 0.81 and 75.91 +/- 3.54%, respectively. The combination index values were <1 when the fraction of affected cells was between 0.2555 and 0.7420. Furthermore, the percentage of apoptotic cells was markedly increased in the combined treatment group when compared with that of the individual treatment groups, in vitro and in vivo. Individual treatment with puerarin resulted in a tumor volume inhibition rate (IR) of 70.58% and a tumor weight IR of 46.20%. Treatment with 5-FU was found to decrease the tumor volume by 76.26% and tumor weight by 49.86%. In the combined treatment group, the tumor volume and weight IRs were 93.11 and 75.21%, respectively. A marked increase in the inhibition of. tumor growth and the number of apoptotic cells in response to combined treatment with puerarin and 5-FU was identified with no observed liver or renal toxicity. These results suggest that puerarin and 5-FU exhibit a synergistic treatment effect on the HCC SMMC7721 cell line.

Aminopeptidase N Inhibitor 4cc Synergizes Antitumor Effects of 5-Fluorouracil on Human Liver Cancer Cells Through ROS-dependent CD13 Inhibition.

Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil.

Novel Aminopeptidase N (APN/CD13) Inhibitor 24F Can Suppress Invasion of Hepatocellular Carcinoma Cells As Well As Angiogenesis.

5-Fluorouracil Nanoparticles Inhibit Hepatocellular Carcinoma Via Activation of the P53 Pathway in the Orthotopic Transplant Mouse Model

Co-administration of Combretastatin A4 Nanoparticles and Anti-Pd-l1 for Synergistic Therapy of Hepatocellular Carcinoma

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

[Anticancer Effect of SN-38 Combined with Sorafenib on Hepatocellular Carcinoma in Vitro and Its Mechanism].

Combined Use of Chemotherapeutics and Oncolytic Adenovirus in Treatment of AFP-expressing Hepatocellular Carcinoma

Synergistic effect of puerarin and 5-fluorouracil on hepatocellular carcinoma.

NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway

Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade

Combination of Calcineurin B Subunit (cnb) and 5-Fluorouracil Reverses 5-Fluorouracil-induced Immunosuppressive Effect and Enhances the Antitumor Activity in Hepatocellular Carcinoma

Amyloid Precursor Protein Regulates 5-Fluorouracil Resistance in Human Hepatocellular Carcinoma Cells by Inhibiting the Mitochondrial Apoptotic Pathway.

Multifunctional Nanoparticles for Targeted Delivery of Apoptin Plasmid in Cancer Treatment

PNAS-4, a Novel Pro-Apoptotic Gene, Can Potentiate Antineoplastic Effects of Cisplatin

Discovery of Novel Tetrahydro-β-carboline Containing Aminopeptidase N Inhibitors as Cancer Chemosensitizers

13F-1, a Novel 5-Fluorouracil Prodrug Containing an Asn–Gly–Arg (NO2) COOCH3 Tripeptide, Inhibits Human Colonic Carcinoma Growth by Targeting Aminopeptidase N (APN/CD13)

A novel anti-alpha-fetoprotein single-chain variable fragment displays anti-tumor effects in HepG2 cells as a single agent or in combination with paclitaxel

A Synergistic Combination of Oleanolic Acid and Apatinib to Enhance Antitumor Effect on Liver Cancer Cells and Protect Against Hepatic Injury

Combination of Angiogenesis Inhibitor TNP-470 with Cytotoxic Drugs in Experimental Therapy of Nasopharyngeal Carcinoma.

Enhanced Anticancer Activity of 5-Fu in Combination with Bestatin: Evidence in Human Tumor-Derived Cell Lines and an H22 Tumor-Bearing Mouse